Title : Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Pub. Date : 2010 Feb 15

PMID : 20145140






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of BCR/ABL by imatinib or nilotinib (AMN107) led to decreased expression of the Plk1 protein in CML cells, suggesting that BCR/ABL promotes Plk1 generation. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Inhibition of BCR/ABL by imatinib or nilotinib (AMN107) led to decreased expression of the Plk1 protein in CML cells, suggesting that BCR/ABL promotes Plk1 generation. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens